Department of Pathology, Jichi Medical University, Japan; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Toho University Ohashi Medical Center, Japan.
Division of Gastroenterology and Hepatology, Department of Internal Medicine, Toho University Ohashi Medical Center, Japan.
Pancreatology. 2018 Jun;18(4):407-412. doi: 10.1016/j.pan.2018.04.003. Epub 2018 Apr 3.
Intraductal papillary mucinous neoplasm (IPMN) of the pancreas is a primary pancreatic ductal epithelial neoplasm with the potential to develop into an invasive adenocarcinoma. This study aimed to investigate the clinicopathologic and prognostic significance of four potential biomarkers for the preoperative evaluation of patients with IPMN.
Clinicopathologic materials from 104 patients with IPMN who underwent surgical resection at Jichi Medical University Hospital were analyzed. IPMNs (110 lesions in total) were histologically classified into low-grade IPMN (Group 1; n = 68), high-grade IPMN (Group 2; n = 16), or IPMN with an associated invasive carcinoma (Group 3; n = 26). We evaluated the immunohistochemical expression of MUC13, AGR2, FUT8, and FXYD3, which were previously reported to be overexpressed in pancreatic ductal adenocarcinoma.
The expression of MUC13 was more common in Group 3 compared with groups 1 and 2 (p < 0.001) and was associated with poor prognosis (p = 0.004). The expression of MUC13 was not associated with age, sex, tumor location, histological subtype, lymphatic or vascular invasion, or neural invasion. In most cases of IPMN, the loss of expression of AGR2 appeared to show an association with tumor recurrence and poorly differentiated histology of invasive carcinoma; however, this association was not statistically significant. The expressions of FUT8 and FXYD3were not associated with the clinicopathological features of IPMNs.
The results suggest that MUC13 overexpression and loss of expression of AGR2 may predict the progression of IPMN and an unfavorable prognosis in patients with IPMN.
胰腺导管内乳头状黏液性肿瘤（IPMN）是一种具有潜在侵袭性腺癌发展潜能的胰腺导管上皮性肿瘤。本研究旨在探讨四种潜在生物标志物在术前评估 IPMN 患者中的临床病理和预后意义。
分析了在日本自治医科大学医院接受手术切除的 104 例 IPMN 患者的临床病理材料。对 110 个 IPMN 病变（总病变数）进行了组织学分类，分为低级别 IPMN（1 组；n=68）、高级别 IPMN（2 组；n=16）或伴有浸润性癌的 IPMN（3 组；n=26）。我们评估了 MUC13、AGR2、FUT8 和 FXYD3 的免疫组织化学表达，这些标志物先前被报道在胰腺导管腺癌中过表达。
MUC13 的表达在 3 组中比在 1 组和 2 组中更为常见（p<0.001），并且与不良预后相关（p=0.004）。MUC13 的表达与年龄、性别、肿瘤位置、组织学亚型、淋巴或血管侵犯或神经侵犯无关。在大多数 IPMN 病例中，AGR2 表达缺失似乎与肿瘤复发和侵袭性癌的低分化组织学有关；然而，这种关联没有统计学意义。FUT8 和 FXYD3 的表达与 IPMN 的临床病理特征无关。
结果表明，MUC13 过表达和 AGR2 表达缺失可能预测 IPMN 的进展和 IPMN 患者的不良预后。
